MétaCan
Menu
← Back to cohort
Record W7120013993 · doi:10.1002/alz70856_107489

Population enrichment strategy using <i>APOE</i> ε4 genotype in tau‐targeting trials for preclinical Alzheimer's disease

2025· article· en· W7120013993 on OpenAlexaff
Laura Rosso, João Pedro Ferrari‐Souza, Lucas Bastos Beltrami, Guilherme Povala, Douglas Teixeira Leffa, Firoza Z Lussier, Wagner S. Brum, Cristiano Schaffer Aguzzoli, Marco Antônio De Bastiani, Andrei Bieger, Giovanna Carello‐Collar, Wyllians Vendramini Borelli, Joseph Therriault, Arthur Macedo, Nesrine Rahmouni, Diogo O. Souza, Bruna Bellaver, Pamela C.L. Ferreira, Pedro Rosa‐Neto, Eduardo R. Zimmer

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsMcGill University
Fundersnot available
KeywordsDiseaseGenotypeAsymptomaticPopulationClinical trial

Abstract

fetched live from OpenAlex

Abstract Background Trials in preclinical Alzheimer's disease (AD) are becoming increasingly important, as AD pathological changes appear decades before dementia onset. Amyloid‐beta (Aβ) pathology and the apolipoprotein E ε4 ( APOE ε4) carriership jointly accelerate tau tangle accumulation. However, the utility of assessing both variables to enhance participant selection for AD trials using tau positron emission tomography (PET) as outcome has not yet been explored. Here, we investigated the implications of considering APOE ε4 status for participant selection in tau‐targeting trials for preclinical AD. Method We analyzed 96 cognitively unimpaired (CU) individuals (aged 57‐90 years) from the ADNI cohort that underwent clinical assessments, APOE genotyping, PET for Aβ ([ 18 F]Florbetapir or [ 18 F]Florbetaben) and tau ([ 18 F]Flortaucipir) at baseline, along with a 2‐year follow‐up. Aβ positivity was determined as global [ 18 F]Florbetapir SUVR >1.11 or [ 18 F]Florbetaben SUVR >1.08. We calculated the sample size required for a hypothetical clinical trial testing a 25% drug effect, with 80% power at alpha level 0.05, to reduce tau‐PET accumulation in the medial temporal lobe (MTL) and neocortex (NEO), along with the total trial costs. Result Table 1 reports the demographic information of the study population. Figure 1 shows enrichment strategies for the selection of participants in a clinical trial aiming at tau PET reduction in CU individuals. In comparison to using only Aβ positivity, the use of APOE ε4 genotyping together with Aβ positivity for population enrichment would reduce the sample size and total costs, respectively, by 28% and 34% in trials targeting tau PET MTL , and by 24% and 36%, respectively, in trials targeting tau PET NEO (Figure 2). Conclusion Our findings suggest that combining APOE ε4 status with Aβ positivity may be a cost‐effective strategy for enriching participant selection in AD tau‐targeting trials focusing on asymptomatic individuals, reducing required sample sizes and trial costs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.054
metaresearch head score (Gemma)0.121
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.054
Threshold uncertainty score0.287

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0540.121
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0020.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0020.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0070.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.139
GPT teacher head0.425
Teacher spread0.286 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→